MIB-626 / Metro International Biotech - LARVOL DELTA

A proof of concept trial of MIB-626, a sirtuin-NAD+ activator, in mild Alzheimer's disease dementia (CTAD 2026) - No abstract available

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol. (PubMed, Kidney Int Rep) - P2 | "The NAD Augmentation in Diabetic Kidney Disease (NAD in DKD) trial is a phase 2a, randomized, multicenter, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of oral pharmaceutical-grade microcrystalline β-NMN (MIB-626) in adults with DKD...The results will inform whether NAD augmentation warrants further evaluation in larger trials statistically powered for long-term kidney outcomes. The study is registered at ClinicalTrials.gov (NCT05759468)."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • CST3

Sirtuin-NAD Activator in Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=22 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Dementia • IGF1

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • CST3

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Brigham and Women's Hospital | Initiation date: Apr 2026 ➔ Jul 2026

Trial initiation date • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders • IGF1

Sirtuin-NAD Activator in Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=22 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | N=50 ➔ 22 | Trial completion date: Dec 2025 ➔ Apr 2026 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Trial completion date • Alzheimer's Disease • CNS Disorders • Dementia • Aβ42 • CSF Aβ42 • IGF1

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Brigham and Women's Hospital | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • CST3

DKD: NAD Augmentation in Diabetes Kidney Disease (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Nov 2026

Trial completion date • Trial primary completion date • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (clinicaltrials.gov) - P2 | N=124 | Completed | Sponsor: Metro International Biotech, LLC | Recruiting ➔ Completed

Trial completion

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Brigham and Women's Hospital

New P1 trial • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders • IGF1

Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial. (PubMed, FASEB Bioadv) - P2 | "Future studies should assess whether a rapid increase in NAD+ by parenteral administration can attenuate disease severity and AKI. Trial Registration: ClinicalTrials.gov Identifier: NCT05038488."

Journal • Acute Kidney Injury • Infectious Disease • Inflammation • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • CST3 • IL6 • TNFA

Nicotinamide Mmononucleotide in Patients Undergoing CABG Surgery (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Brigham and Women's Hospital

New P2 trial • CST3

Sirtuin-NAD Activator in Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Aβ42 • CHI3L1 • CSF Aβ42 • GFAP

Phase 2a MIB-626 vs. Placebo COVID-19 (clinicaltrials.gov) - P2 | N=42 | Completed | Sponsor: Metro International Biotech, LLC | Recruiting ➔ Completed | Phase classification: P2a ➔ P2

Phase classification • Trial completion • Acute Kidney Injury • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease • CST3

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Metro International Biotech, LLC | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2023 ➔ Oct 2023

Enrollment open • Trial initiation date

NAD+ Precursor Supplementation in Friedreich's Ataxia (clinicaltrials.gov) - P2a | N=7 | Completed | Sponsor: Metro International Biotech, LLC | Active, not recruiting ➔ Completed | N=10 ➔ 7

Enrollment change • Trial completion • Ataxia • Congestive Heart Failure • Friedreich ataxia • Movement Disorders

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Metro International Biotech, LLC | Phase classification: P1 ➔ P2

Phase classification

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Metro International Biotech, LLC

New P1 trial

"I think MIB626 Will solve the Alzheimer's issue." (,@xrpnft_s)

Alzheimer's Disease • CNS Disorders

DKD: NAD Augmentation in Diabetes Kidney Disease (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • IL6 • KIM1 • TNFA • TNFRSF1A

Phase 2a MIB-626 vs. Placebo COVID-19 (clinicaltrials.gov) - P2a | N=50 | Recruiting | Sponsor: Metro International Biotech, LLC | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Apr 2022 ➔ Jul 2023

Trial completion date • Trial primary completion date • Acute Kidney Injury • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease • CRP • CST3 • IL6 • KIM1 • TNFA

DKD: NAD Augmentation in Diabetes Kidney Disease (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: Brigham and Women's Hospital

New P2 trial • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • IL6 • KIM1 • TNFA • TNFRSF1A

Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. (PubMed, J Clin Endocrinol Metab) - "MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults."

Journal • Dyslipidemia • Obesity

NAD+ Precursor Supplementation in Friedreich's Ataxia (clinicaltrials.gov) - P2a | N=10 | Active, not recruiting | Sponsor: Metro International Biotech, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2023 ➔ May 2023 | Trial primary completion date: Sep 2022 ➔ May 2022

Enrollment closed • Trial completion date • Trial primary completion date • Ataxia • Congestive Heart Failure • Friedreich ataxia • Movement Disorders

Sirtuin-NAD Activator in Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Dementia • IGF1 • IL6 • TNFA